反复应用碘消毒剂可否导致人体过量摄碘的研究
摘要
背景：以碘元素为有效成分的消毒剂在医学领域有着广泛的应用。外科医生在术前进行手部消毒时,含碘消毒剂一直是在世界范围内最经典的、应用最广的选择。碘元素同时是甲状腺激素的合成原料,碘的缺乏可引起多种甲状腺疾病。2001年以来,人们开始认识到,碘的摄入过量同样可使多种甲状腺疾病的发病率增加目的：探讨外科医生反复应用含碘消毒剂进行术前手部消毒是否会引起碘元素过量摄入。方法：使用国际公认的测定方法对上海中山医院长期使用安尔碘刷手的外科医生和器械护士的碘摄入水平进行测定,并在该医院使用新型消毒剂替换安尔碘之后对同样的样本再次进行了测定,作为自身对照。结果：经过对71例样本和61例对照样本的结果分析,发现该人群并不存在碘摄入过量,并且停用含碘消毒剂后该人群碘的摄入水平亦无显著下降。
Background: Disinfectants containing iodine are widely used in medicine field. It has been most commonly chosen by surgeons as the classic disinfectant for pre-operative scrub. Iodine is also a material for the thyroid gland to produce thyroid hormone, and the inadequate intake of iodine has been known to contribute to thyroid diseases. On the year 2001, it was known that the overdosed intake of iodine can also cause many kinds of thyroid diseases. Object: To determine whether repeated use of iodine as surgery scrub will causes overdosed intake of iodine. Methods: Determine the level of iodine intake of a group of surgeons and scrub nurses in Zhongshan Hospital who have been intensively using iodine as per-operative hand scrub, Then run the test again to the same group of people as a self-control after the hospital replaced the disinfectant with a new one without iodine, and contrast the results of the two times. Results: After analyzing the result from the specimen of 71 people and their self-control, it is believed that the intensive use of disinfectant with iodine does not cause overdosed iodine intake, and that after stop using it there is no significent decrease of the level of the iodine intake.
Background: Disinfectants containing iodine are widely used in medicine field. It has been most commonly chosen by surgeons as the classic disinfectant for pre-operative scrub. Iodine is also a material for the thyroid gland to produce thyroid hormone, and the inadequate intake of iodine has been known to contribute to thyroid diseases. On the year 2001, it was known that the overdosed intake of iodine can also cause many kinds of thyroid diseases. Object: To determine whether repeated use of iodine as surgery scrub will causes overdosed intake of iodine. Methods: Determine the level of iodine intake of a group of surgeons and scrub nurses in Zhongshan Hospital who have been intensively using iodine as per-operative hand scrub, Then run the test again to the same group of people as a self-control after the hospital replaced the disinfectant with a new one without iodine, and contrast the results of the two times. Results: After analyzing the result from the specimen of 71 people and their self-control, it is believed that the intensive use of disinfectant with iodine does not cause overdosed iodine intake, and that after stop using it there is no significent decrease of the level of the iodine intake.
引文
1. Widmer, A.F., M. Rotter, A. Voss, et al., Surgical hand preparation: state-of-the-art. J Hosp Infect, 2010.74(2):p.112-22.
2. WHO/UNICEF/ICCDD, Assessment of the iodine deficiency disorders and monitoring their elimination. Geneva:WHO,2001.
3. 滕晓春,滕卫平,碘过量与甲状腺疾病.实用医院临床杂志,2007.4(5)：p.5-7.
4. Teng, W., Z. Shan, X. Teng, et al., Effect of iodine intake on thyroid diseases in China. N Engl J Med, 2006.354(26):p.2783-93.
5. RNiedner, Cytotoxicity and sensitization of povidone-iodine and other frequently used anti-infective agents. Dermatology,1997.195(Suppl 2):p.89-92.
6. Benson, H.A., Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv, 2005.2(1):p.23-33.
7. Cross, S.E. M.S. Roberts, Physical enhancement of transdermal drug application: is delivery technology keeping up with pharmaceutical development? Curr Drug Deliv,2004.1(1):p.81-92.
8. 王斐,赵世华,赵文德,尿碘测定方法学进展.中国地方病防治杂志,2000.15(3)：p.147-148.
9. 陈祖培,尿碘的测定及其临床意义.中国地方病学杂志,1997.16(1)：p.35-37.
10.107-2006,WT,尿中碘的砷铈催化分光光度测定方法.
1. WHO/UNICEF/ICCDD, Assessment of the iodine deficiency disorders and monitoring their elimination. Geneva:WHO,2001.
2. Hugo, W.B., A brief history of heat and chemical preservation and disinfection. J Appl Bacteriol,1991. 71(1):p.9-18.
3. McDonnell, G. andA.D. Russell, Antiseptics and disinfectants:activity, action, and resistance. Clin Microbiol Rev,1999.12(1):p.147-79.
4. Zamora, J.L., Chemical and microbiologic characteristics and toxicity of povidone-iodine solutions. Am J Surg,1986.151(3):p.400-6.
5. Fleischer, W. andK. Reimer, Povidone-iodine in antisepsis--state of the art. Dermatology,1997.195 Suppl 2:p.3-9.
6. R.Niedner, Cytotoxicity and sensitization of povidone-iodine and other frequently used anti-infective agents. Dermatology,1997.195(Suppl 2):p.89-92.
7. Rotter, M., W. Koller, and G. Wewalka, Povidone-iodine and chlorhexidine gluconate-containing detergents for disinfection of hands. J Hosp Infect,1980.1(2):p.149-58.
8. Boyce, J.M., Methicillin-resistant Staphylococcus aureus in hospitals and long-term care facilities: microbiology, epidemiology, and preventive measures. Infect Control Hosp Epidemiol,1992.13(12): p.725-37.
9. Guilhermetti, M., S.E. Hemandes, Y. Fukushigue, et al., Effectiveness of hand-cleansing agents for removing methicillin-resistant Staphylococcus aureus from contaminated hands. Infect Control Hosp Epidemiol,2001.22(2):p.105-8.
10. Paulson, D.S., Comparative evaluation of five surgical hand scrub preparations. AORN J,1994.60(2): p.246,249-56.
11. Wade, J.J. andM.W. Casewell, The evaluation of residual antimicrobial activity on hands and its clinical relevance. J Hosp Infect,1991.18 Suppl B:p.23-8.
12. O'Shaughnessy, M., V.P.OMalley, G. Corbett, et al., Optimum duration of surgical scrub-time. Br J Surg,1991.78(6):p.685-6.
13. Aksoy, A., F. Caglayan, M. Cakmak, et al., An investigation of the factors that affect surgical hand disinfection with polyvidone iodine. J Hosp Infect,2005.61(1):p.15-9.
14. Todd, C.H., T. Allain, Z.A. Gomo, et al., Increase in thyrotoxicosis associated with iodine supplements in Zimbabwe. Lancet,1995.346(8989):p.1563-4.
15. A, M., G. G, and B. P, The incidence of hyperthyroidism in Austria from 1987 to 1995 before and after an increase in salt iodization in 1990. Eur J NuclMed,1998.25(4):p.367-374.
16. Bulow Pedersen, I., P. Laurberg, N. Knudsen, et al., Increase in incidence of hyperthyroidism predominantly occurs in young people after iodine fortification of salt in Denmark. J Clin Endocrinol Metab,2006.91(10):p.3830-4.
17. Teng, W., Z. Shan, X. Teng, et al., Effect of iodine intake on thyroid diseases in China. N Engl J Med, 2006.354(26):p.2783-93.
18. Solomon, B.L., J.E. Evaul, K.D. Burman, et al., Remission rates with antithyroid drug therapy: continuing influence of iodine intake? Ann Intern Med,1987.107(4):p.510-2.
19. Slowinska-Klencka, D., M. Klencki, S. Spomy, et al., Fine-needle aspiration biopsy of the thyroid in an area of endemic goitre: influence of restored sufficient iodine supplementation on the clinical significance of cytological results. Eur J Endocrinol,2002.146(1):p.19-26.
20. Zois, C., I. Stavrou, G Kalogera, et al., High prevalence of autoimmune thyroiditis in schoolchildren after elimination of iodine deficiency in northwestern Greece. Thyroid,2003.13(5):p.485-9.
21. LDKE., P., ParkesAB., and S. PPA, Increased p revalence of thyroglobulin antibodies in Sri Lankan schoolgirls is iodine the cause? Euro J Endocrinol,2000.143:p.185-188.
22. HX., G., L. CY., and TengWP, High iodine intake is a risk factor of post-partum thyroiditis:result of a survey from Shenyang, China. J Endocrinol Invest,2005.28(10):p.876-881.
23. Bacher-Stier, C., G. Riccabona, M. Totsch, et al., Incidence and clinical characteristics of thyroid carcinoma after iodine prophylaxis in an endemic goiter country. Thyroid,1997.7(5):p.733-41.
24. Mitchell IM, Pollock JC, Jamieson MP, et al., Transcutaneous iodine absorption in infants undergoing cardiac operation. Ann Thorac Surg,1991.52:p.1138-1140.
25. Chabrolle, J.P. andA. Rossier, Goitre and hypothyroidism in the newborn after cutaneous absorption of iodine. Arch Dis Child,1978.53(6):p.495-8.
26. Vorherr, H., U.F. Vorherr, P. Mehta, et al., Vaginal absorption of povidone-iodine. JAMA,1980. 244(23):p.2628-9.
27. Safran, M. andL.E. Braverman, Effect of chronic douching with polyvinylpyrrolidone-iodine on iodine absorption and thyroid function. Obstet Gynecol,1982.60(1):p.35-40.
28. Lavelle, K.J., D.J. Doedens, S.A. Kleit, et al., Iodine absorption in burn patients treated topically with povidone-iodine. Clin Pharmacol Ther,1975.17(3):p.355-62.
29. Rath, T. andG. Meissl, Induction of hyperthyroidism in bum patients treated topically with povidone-iodine. Bums Incl Therm Inj,1988.14(4):p.320-2.
30. Nobukuni, K. andS. Kawahara, Thyroid function in nurses: the influence of povidone-iodine hand washing and gargling. Dermatology,2002.204 Suppl 1:p.99-102.
31. Ader, A.W., T.L. Paul, W. Reinhardt, et al., Effect of mouth rinsing with two polyvinylpyrrolidone-iodine mixtures on iodine absorption and thyroid function. J Clin Endocrinol Metab,1988.66(3):p.632-5.
32. Tomoda, C., H. Kitano, T. Uruno, et al., Transcutaneous iodine absorption in adult patients with thyroid cancer disinfected with povidone-iodine at operation. Thyroid,2005.15(6):p.600-3.
33. Purdon, C.H., C.G. Azzi, J. Zhang, et al., Penetration enhancement of transdermal delivery--current permutations and limitations. Crit Rev Ther Drug Carrier Syst,2004.21(2):p.97-132.
34. Benson, H.A., Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv, 2005.2(1):p.23-33.
35. Nanda, A., S. Nanda, and N.M. Ghilzai, Current developments using emerging transdermal technologies in physical enhancement methods. Curr Drug Deliv,2006.3(3):p.233-42.
36. Tanner, J., Surgical hand antisepsis: the evidence. J Perioper Pract,2008.18(8):p.330-4,339.
37. Hsieh, H.F., H.H. Chiu, and F.P. Lee, Surgical hand scrubs in relation to microbial counts: systematic literature review. J Adv Nurs,2006.55(1):p.68-78.
38. Tanwar, Y.S., C.S. Chauhan, and A. Sharma, Development and evaluation of carvedilol transdermal patches. Acta Pharm,2007.57(2):p.151-9.
1. Hirsch, A.T., Z.J. Haskal, N.R. Hertzer, et al., ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic):a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation,2006.113(11):e463-654.
2. Prostanoids for chronic critical leg ischemia. A rand omized, controlled, open-label trial with prostagland in E1. The ICAI Study Group. Ischemia Cronica degli Arti Inferiori. Ann Intern Med, 1999.130(5):412-21.
3. Albers, M., A.C. Fratezi and N. De Luccia, Assessment of quality of life of patients with severe ischemia as a result of infrainguinal arterial occlusive disease. J Vasc Surg,1992.16(1):54-9.
4. Davies, N., S. Dobner, D. Bezuidenhout, et al., The dosage dependence of VEGF stimulation on scaffold neovascularisation. Biomaterials,2008.29(26):3531-8.
5. Adams, R.H. and K. Alitalo, Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol,2007.8(6):464-78.
6. Carmeliet, P., Mechanisms of angiogenesis and arteriogenesis. Nat Med,2000.6(4):389-95.
7. Helisch, A. and W. Schaper, Arteriogenesis: the development and growth of collateral arteries. Microcirculation,2003.10(1):83-97.
8. Simons, M., Angiogenesis: where do we stand now? Circulation,2005.111(12):1556-66.
9. Murray, C.D., The Physiological Principle of Minimum Work: I. The Vascular System and the Cost of Blood Volume. Proc Natl Acad Sci U S A,1926.12(3):207-14.
10. Phelps, E.A. and A.J. Garcia, Update on therapeutic vascularization strategies. Regen Med,2009.4(1): 65-80.
11. Chen, R.R., E.A. Silva, W.W. Yuen, et al., Integrated approach to designing growth factor delivery systems. FASEB J,2007.21(14):3896-903.
12. Gerhardt, H., M. Golding, M. Fruttiger, et al., VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol,2003.161(6):1163-77.
13. Dellian, M., B.P. Witwer, H.A. Salehi, et al., Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am J Pathol,1996.149(1):59-71.
14. Hao, X., E.A. Silva, A. Mansson-Broberg, et al., Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc Res,2007. 75(1):178-85.
15. Chen, R.R., E.A. Silva, W.W. Yuen, et al., Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm Res,2007.24(2):258-64.
16. Richardson, T.P., M.C. Peters, AB. Ennett, et al., Polymeric system for dual growth factor delivery. Nat Biotechnol,2001.19(11):1029-34.
17. Marui, A, A Kanematsu, K. Yamahara, et al., Simultaneous application of basic fibroblast growth factor and hepatocyte growth factor to enhance the blood vessels formation. J Vasc Surg,2005.41(1): 82-90.
18. Shyu, K.G., H. Chang and J.M. Isner, Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. Life Sci,2003.73(5):563-79.
19. Rajagopalan, S., J. Olin, S. Deitcher, et al., Use of a constitutively active hypoxia-inducible factor- 1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation,2007.115(10):1234-43.
20. Carmeliet, P., VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med,2000. 6(10):1102-3.
21. Marui, A., Y. Tabata, S. Kojima, et al., A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel: an initial report of the phase I-IIa study. Gire J,2007.71(8):1181-6.
22. Bobek, V., O. Taltynov, D. Pinterova, et al., Gene therapy of the ischemic lower limb--Therapeutic angiogenesis. Vascul Pharmacol,2006.44(6):395-405.
23. Isner, J.M., A. Pieczek, R Schainfeld, et al., Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet,1996.348(9024):370-4.
24. Makinen, K., H. Manninen, M. Hedman, et al., Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a rand omized, placebo-controlled, double-blinded phase II study. Mol Ther,2002.6(1):127-33.
25. Kusumanto, Y.H., V. van Weel, N.H. Mulder, et al., Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind rand omized trial. Hum Gene Ther,2006.17(6):683-91.
26. Comerota, A.J., R.C. Throm, K.A. Miller, et al., Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg,2002.35(5):930-6.
27. Nikol, S., I. Baumgartner, E. Van Belle, et al., Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther,2008.16(5): 972-8.
28. Powell, RJ., M. Simons, F.O. Mendelsohn, et al., Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation,2008.118(1):58-65.
29. Chae, J.K., I. Kim, S.T. Lim, et al., Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler Thromb Vasc Biol,2000.20(12): 2573-8.
30. Suri, C., J. McClain, G. Thurston, et al., Increased vascularization in mice overexpressing angiopoietin-1. Science,1998.282(5388):468-71.
31. Asahara, T., T. Murohara, A. Sullivan, et al., Isolation of putative progenitor endothelial cells for angiogenesis. Science,1997.275(5302):964-7.
32. Friedrich, E.B., K. Walenta, J. Scharlau, et al., CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res,2006.98(3):e20-5.
33. Peichev, M., A.J. Naiyer, D. Pereira, et al., Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood,2000.95(3):952-8.
34. Pelosi, E., M. Valtieri, S. Coppola, et al., Identification of the hemangioblast in postnatal life. Blood, 2002.100(9):3203-8.
35. Shi, Q., S. Rafii, M.H. Wu, et al., Evidence for circulating bone marrow-derived endothelial cells. Blood,1998.92(2):362-7.
36. Wassmann, S., N. Wemer, T. Czech, et al., Improvement of endothelial function by systemic transfusion of vascular progenitor cells. Circ Res,2006.99(8):e74-83.
37. Griese, D.P., A. Ehsan, L.G. Melo, et al., Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts:implications for cell-based vascular therapy. Circulation,2003.108(21):2710-5.
38. Kong, D., L.G. Melo, M. Gnecchi, et al., Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation,2004.110(14):2039-46.
39. Crosby, J.R, W.E. Kaminski, G. Schatteman, et al., Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Girc Res,2000.87(9):728-30.
40. Kalka, C., H. Masuda, T. Takahashi, et al., Transplantation of ex vivo expand ed endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A,2000.97(7):3422-7.
41. Rehman, J., J. Li, C.M. Orschell, et al., Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation,2003.107(8): 1164-9.
42. Murayama, T., OM Tepper, M. Silver, et al., Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo. Exp Hematol,2002.30(8):967-72.
43. Tateishi-Yuyama, E., H. Matsubara, T. Murohara, et al., Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a rand omised controlled trial. Lancet,2002.360(9331):427-35.
44. Ziegelhoeffer, T., B. Fernand ez, S. Kostin, et al., Bone marrow-derived cells do not incorporate into the adult growing vasculature. Clrc Res,2004.94(2):230-8.
45. Assmus, B., V. Schachinger, G Teupe, et al., Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation,2002.106(24):3009-17.
46. Huang, P.P., X.F. Yang, S.Z. Li, et al., Rand omised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost,2007.98(6):1335-42.
47. Jiang, Y., B.N. Jahagirdar, RL. Reinhardt, et al., Pluripotency of mesenchymal stem cells derived from adult marrow. Nature,2002.418(6893):41-9.
48. Chamberlain, G., J. Fox, B. Ashton, et al., Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells,2007.25(11): 2739-49.
49. Psaltis, P.J., A.G Zannettino, S.G. Worthley, et al., Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells,2008.26(9):2201-10.
50. Kawamoto, A., T. Tkebuchava, J. Yamaguchi, et al., Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation, 2003.107(3):461-8.
51. Kinnaird, T., E. Stabile, M.S. Burnett, et al., Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation,2004.109(12):1543-9.
52. Suuronen, E.J., J. Price, J.P. Veinot, et al., Comparative effects of mesenchymal progenitor cells, endothelial progenitor cells, or their combination on myocardial infarct regeneration and cardiac function. J Thorac Cardiovasc Surg,2007.134(5):1249-58.
1 Park KH, Lim C, et al, Prevalence of aortic intimal defect in surgically treated acute type A intramural hematoma, Ann Thorac Surg.2008 Nov;86(5):1501.
2 Coady MA, Rizzo JA, Elefteriades JA. Pathologic variants of thoracic aortic dissections. Penetrating atherosclerotic ulcers and intramural hematomas. Cardiol Clin 1999;17:637-57.
3 Nienaber CA, Sievers HH. Intramural hematoma in acute aortic syndrome: more than one variant of dissection? Circulation.2002,406:284-285.
4 Ganaha F; Miller DC, et al, Prognosis of aortic intramural hematoma with and without penetrating atherosclerotic ulcer: a clinical and radiological analysis. Circulation 2002 Jul 16;106(3):342-8.
5 Cho KR, Stanson AW, Potter DD, et al. Penetrating atherosclerotic ulcer of the descending thoracic aorta and arch. J Thorac Cardiovasc Surg 2004;127:1393-401.
6 Sundt TM.Intramural hematoma and penetrating atherosclerotic ulcer of the aorta-Ann Thorac Surg.2007 Feb;83(2):S835-41; discussion S846-50.
7 Meszaros I; Morocz J, et al, Epidemiology and clinicopathology of aortic dissection, Chest 2000 May,117(5):1271-8.
8 Clouse WD; Hallett JW Jr, et al, Acute aortic dissection: population-based incidence compared with degenerative aortic aneurysm rupture, Mayo Glin Proc 2004 Feb;79(2):176-80.
9 Hagan PG; Nienaber CA; et al, The International Registry of Acute Aortic Dissection (IRAD):new insights into an old disease, JAMA 2000 Feb 16;283(7):897-903.
10 Nienaber CA; Fattori R, et al, Gender-related differences in acute aortic dissection, Circulation 2004 Jun 22;109(24):3014-21. Epub 2004 Jun 14.
11 Evangelista A; Mukherjee D, et al, Acute intramural hematoma of the aorta: a mystery in evolution. Circulation 2005 Mar 1;111(8):1063-70. Epub 2005 Feb 14.
12 Nienaber CA; Eagle KA, Aortic dissection: new frontiers in diagnosis and management: Part Ⅰ:from etiology to diagnostic strategies. Circulation 2003 Aug 5;108(5):628-35.
13 Nallamothu BK, Mehta RH, et al, Syncope in acute aortic dissection: diagnostic, prognostic, and clinical implications. Am J Med.2002;113:468-471.
14 Park SW; Hutchison S, et al, Association of painless acute aortic dissection with increased mortality. Mayo Clin Proc 2004 Oct;79(10):1252-7.
15 Kamp TJ, Goldschmidt-Clermont PJ, et al, Myocardial infarction, aortic dissection, and thrombolytic therapy. Am Heart J.1994;128:1234-1237.
16 Hansen MS, Nogareda GJ, Hutchison SJ. Frequency of and inappropriate treatment of misdiagnosis of acute aortic dissection. Am J Cardiol.2007 Mar 15;99(6):852-6.
17 von Kodolitsch Y; Schwartz AG; Nienaber CA, Clinical prediction of acute aortic dissection, Arch Intern Med 2000 Oct 23;160(19):2977-82.
18 Vilacosta I; San Roman JA, et al, Natural history and serial morphology of aortic intramural hematoma: a novel variant of aortic dissection. Am Heart J 1997 Sep;134(3):495-507.
19 Ohlmann P, Faure A, et al, Lower circulating Sta-Liatest D-Di levels in patients with aortic intramural hematoma compared with classical aortic dissection. Crit Care Med.2009 Mar;37(3):899-901.
20 Isselbacher EM; Gigarroa JE; Eagle KA, Cardiac tamponade complicating proximal aortic dissection. Is pericardiocentesis harmful? Circulation 1994 Nov;90(5):2375-8.
21 Tsai TT; Evangelista A, et al, Partial thrombosis of the false lumen in patients with acute type B aortic dissection. N Engl J Med.2007 Jul 26;357(4):349-59.
22 Mehta RH; O'Gara PT, et al, Acute type A aortic dissection in the elderly: clinical characteristics, management, and outcomes in the current era. J Am Coll Cardiol 2002 Aug 21;40(4):685-92.
23 Jakob H, Tsagakis K, et al, Combining classic surgery with descending stent grafting for acute DeBakey type I dissection. Ann Thorac Surg.2008 Jul;86(1):101-2.
24 Penn MS; Smedira N, et al, Does coronary angiography before emergency aortic surgery affect in-hospital mortality? J Am Coll Cardiol 2000 Mar 15;35(4):889-94.
25 DeSanctis RW;Doroghazi RM, et al. Aortic dissection. N Engl J Med 1987 Oct22;317(17):1060-7.
26 Umana JP; Lai DT, et al, Is medical therapy still the optimal treatment strategy for patients with acute type B aortic dissections? J Thorac Cardiovasc Surg 2002 Nov;124(5):896-910.
27 Shimokawa T, Horiuchi K, et al, Outcome of surgical treatment in patients with acute type B aortic dissection, Ann Thorac Surg.2008 Jul;86(1):107-8.
28 Kusagawa H; Shimono T, et al, Changes in false lumen after transluminal stent-graft placement in aortic dissections: six years experience, Circulation 2005 Jun 7;111(22):2951-7. Epub 2005 May31.
29 王深明,Stanford A型主动脉夹层的血管腔内治疗,外科理论与实践,2007,12(1)：7-9.
30 常光其,李晓曦,等,腔内修复联合旁路手术治疗DeBakey I型升主动脉夹层,中华实用外科杂志,2005,25(12)
31 Eggebrecht H; Nienaber CA, et al, Endovascular stent-graft placement in aortic dissection: a meta-analysis, Eur Heart J.2006 Feb;27(4):489-498. Epub 2005 Oct 14.
32 Parker JD, Golledge J. Outcome of endovascular treatment of acute type B aortic dissection. Ann Thorac Surg.2008 Nov;86(5):1707-12.
33 Nienaber CA; Fattori R, et al, Nonsurgical reconstruction of thoracic aortic dissection by stent-graft placement. N Engl J Med 1999 May20;340(20):1539-45.
34 Endovascular therapy for Stanford type B aortic dissection in 102 cases. Asian Journal of Surgery. 2005,28(4):271-276.
35 石赞,符伟国等,150例Stanford B型主动脉夹层动脉瘤的手术回顾。外科理论与实践,2005,10(1)：45-49.
36 Strategies for managing the insufficiency of the proximal landing zone during endovascular thoracic aortic repair. Chinese Medical Journal,2005,118(13):1066-1071.
37 邵明哲,符伟国等,累及肠系膜上动脉的Stanford B型夹层主动脉瘤的治疗.中华普通外科杂志,200722(1)：58-60.
38 Retrograde Type A Aortic Dissection Following Endovascular Stent-graft Placement for Treatment of Type B Dissection. Circulation,2009,February 10,735-744.
39 Slonim SM; Miller DC, et al, Percutaneous balloon fenestration and stenting for life-threatening ischemic complications in patients with acute aortic dissection. J Thorac Cardiovasc Surg 1999 Jun;117(6):1118-26.
40 Erbel R; Alfonso F, et al, Diagnosis and management of aortic dissection. Eur Heart J 2001 Sep;22(18):1642-81.
41 Maraj R; Rerkpattanapipat P, et al, Meta-analysis of 143 reported cases of aortic intramural hematoma. Am J Cardiol 2000 Sep 15;86(6):664-8.
42 von Kodolitsch Y; Csosz SK, et al, Intramural hematoma of the aorta: predictors of progression to dissection and rupture. Circulation 2003 Mar 4;107(8):1158-63.
43 Shimokawa T, Ozawa N, et al, Intermediate-term results of surgical treatment of acute intramural hematoma involving the ascending aorta. Ann Thorac Surg.2008 Mar,85(3):982-6
44 Moizumi Y; Komatsu T, et al, Clinical features and long-term outcome of type A and type B intramural hematoma of the aorta, J Thorac Cardiovasc Surg 2004 Feb;127(2):421-7.
45 Kaji S; Akasaka T, et al, Long-term prognosis of patients with type B aortic intramural hematoma. Circulation 2003 Sep 9;108 Suppl 1:Ⅱ307-11.
46 Tittle SL, Lynch RJ, Cole PE, et al. Midterm follow-up of penetrating ulcer and intramural hematoma of the aorta. J Thorac Cardiovasc Surg 2002;123:1051-9.
47 Stanson AW, Kazmier FJ, et al. Penetrating atherosclerotic ulcers of the thoracic aorta: natural history and clinicopathologic correlations. Ann Vasc Surg 1986;1:15-23.
48 Coady MA, Rizzo JA, et al. Penetrating ulcer of the thoracic aorta: what is it? How do we recognize it? How do we manage it? J Vasc Surg 1998;27:1006-1015
49 Grabenwoger M, Fleck T, Czerny M, et al. Endovascular stent graft placement in patients with acute thoracic aortic syndromes. Eur J Cardiothorac Surg 2003;23:788-93.
50 Demers P; Miller DC, et al, Stent-graft repair of penetrating atherosclerotic ulcers in the descending thoracic aorta: mid-term results. Ann Thorac Surg 2004 Jan;77(1):81-6.
51 Botta L, Buttazzi K, et al, Endovascular repair for penetrating aatherosclerotic ulcers of the descending thoracic aorta: early and mid-term result. Ann Thorac Surg 2008 Mar;85(3):987-92
52 Brinster DR, Wheatley GH 3rd, et al. Are penetrating aortic ulcers best treated using an endovascular approach, Ann Thorac Surg.2006 Nov;82(5):1688-91.
53 Dalainas I, Nano G, et al. Endovascular treatment of penetrating aortic ulcers: mid-term results. Eur J Vasc Endovasc Surg.2007 Jul;34(1):74-8.
54 Girn HR, McPherson S, et al. Short series of emergency stent-graft repair of symptomatic penetrating thoracic aortic ulcers (PTAU). Vasc Med.2009 May;14(2):123-8.
2. WHO/UNICEF/ICCDD, Assessment of the iodine deficiency disorders and monitoring their elimination. Geneva:WHO,2001.
3. 滕晓春,滕卫平,碘过量与甲状腺疾病.实用医院临床杂志,2007.4(5)：p.5-7.
4. Teng, W., Z. Shan, X. Teng, et al., Effect of iodine intake on thyroid diseases in China. N Engl J Med, 2006.354(26):p.2783-93.
5. RNiedner, Cytotoxicity and sensitization of povidone-iodine and other frequently used anti-infective agents. Dermatology,1997.195(Suppl 2):p.89-92.
6. Benson, H.A., Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv, 2005.2(1):p.23-33.
7. Cross, S.E. M.S. Roberts, Physical enhancement of transdermal drug application: is delivery technology keeping up with pharmaceutical development? Curr Drug Deliv,2004.1(1):p.81-92.
8. 王斐,赵世华,赵文德,尿碘测定方法学进展.中国地方病防治杂志,2000.15(3)：p.147-148.
9. 陈祖培,尿碘的测定及其临床意义.中国地方病学杂志,1997.16(1)：p.35-37.
10.107-2006,WT,尿中碘的砷铈催化分光光度测定方法.
1. WHO/UNICEF/ICCDD, Assessment of the iodine deficiency disorders and monitoring their elimination. Geneva:WHO,2001.
2. Hugo, W.B., A brief history of heat and chemical preservation and disinfection. J Appl Bacteriol,1991. 71(1):p.9-18.
3. McDonnell, G. andA.D. Russell, Antiseptics and disinfectants:activity, action, and resistance. Clin Microbiol Rev,1999.12(1):p.147-79.
4. Zamora, J.L., Chemical and microbiologic characteristics and toxicity of povidone-iodine solutions. Am J Surg,1986.151(3):p.400-6.
5. Fleischer, W. andK. Reimer, Povidone-iodine in antisepsis--state of the art. Dermatology,1997.195 Suppl 2:p.3-9.
6. R.Niedner, Cytotoxicity and sensitization of povidone-iodine and other frequently used anti-infective agents. Dermatology,1997.195(Suppl 2):p.89-92.
7. Rotter, M., W. Koller, and G. Wewalka, Povidone-iodine and chlorhexidine gluconate-containing detergents for disinfection of hands. J Hosp Infect,1980.1(2):p.149-58.
8. Boyce, J.M., Methicillin-resistant Staphylococcus aureus in hospitals and long-term care facilities: microbiology, epidemiology, and preventive measures. Infect Control Hosp Epidemiol,1992.13(12): p.725-37.
9. Guilhermetti, M., S.E. Hemandes, Y. Fukushigue, et al., Effectiveness of hand-cleansing agents for removing methicillin-resistant Staphylococcus aureus from contaminated hands. Infect Control Hosp Epidemiol,2001.22(2):p.105-8.
10. Paulson, D.S., Comparative evaluation of five surgical hand scrub preparations. AORN J,1994.60(2): p.246,249-56.
11. Wade, J.J. andM.W. Casewell, The evaluation of residual antimicrobial activity on hands and its clinical relevance. J Hosp Infect,1991.18 Suppl B:p.23-8.
12. O'Shaughnessy, M., V.P.OMalley, G. Corbett, et al., Optimum duration of surgical scrub-time. Br J Surg,1991.78(6):p.685-6.
13. Aksoy, A., F. Caglayan, M. Cakmak, et al., An investigation of the factors that affect surgical hand disinfection with polyvidone iodine. J Hosp Infect,2005.61(1):p.15-9.
14. Todd, C.H., T. Allain, Z.A. Gomo, et al., Increase in thyrotoxicosis associated with iodine supplements in Zimbabwe. Lancet,1995.346(8989):p.1563-4.
15. A, M., G. G, and B. P, The incidence of hyperthyroidism in Austria from 1987 to 1995 before and after an increase in salt iodization in 1990. Eur J NuclMed,1998.25(4):p.367-374.
16. Bulow Pedersen, I., P. Laurberg, N. Knudsen, et al., Increase in incidence of hyperthyroidism predominantly occurs in young people after iodine fortification of salt in Denmark. J Clin Endocrinol Metab,2006.91(10):p.3830-4.
17. Teng, W., Z. Shan, X. Teng, et al., Effect of iodine intake on thyroid diseases in China. N Engl J Med, 2006.354(26):p.2783-93.
18. Solomon, B.L., J.E. Evaul, K.D. Burman, et al., Remission rates with antithyroid drug therapy: continuing influence of iodine intake? Ann Intern Med,1987.107(4):p.510-2.
19. Slowinska-Klencka, D., M. Klencki, S. Spomy, et al., Fine-needle aspiration biopsy of the thyroid in an area of endemic goitre: influence of restored sufficient iodine supplementation on the clinical significance of cytological results. Eur J Endocrinol,2002.146(1):p.19-26.
20. Zois, C., I. Stavrou, G Kalogera, et al., High prevalence of autoimmune thyroiditis in schoolchildren after elimination of iodine deficiency in northwestern Greece. Thyroid,2003.13(5):p.485-9.
21. LDKE., P., ParkesAB., and S. PPA, Increased p revalence of thyroglobulin antibodies in Sri Lankan schoolgirls is iodine the cause? Euro J Endocrinol,2000.143:p.185-188.
22. HX., G., L. CY., and TengWP, High iodine intake is a risk factor of post-partum thyroiditis:result of a survey from Shenyang, China. J Endocrinol Invest,2005.28(10):p.876-881.
23. Bacher-Stier, C., G. Riccabona, M. Totsch, et al., Incidence and clinical characteristics of thyroid carcinoma after iodine prophylaxis in an endemic goiter country. Thyroid,1997.7(5):p.733-41.
24. Mitchell IM, Pollock JC, Jamieson MP, et al., Transcutaneous iodine absorption in infants undergoing cardiac operation. Ann Thorac Surg,1991.52:p.1138-1140.
25. Chabrolle, J.P. andA. Rossier, Goitre and hypothyroidism in the newborn after cutaneous absorption of iodine. Arch Dis Child,1978.53(6):p.495-8.
26. Vorherr, H., U.F. Vorherr, P. Mehta, et al., Vaginal absorption of povidone-iodine. JAMA,1980. 244(23):p.2628-9.
27. Safran, M. andL.E. Braverman, Effect of chronic douching with polyvinylpyrrolidone-iodine on iodine absorption and thyroid function. Obstet Gynecol,1982.60(1):p.35-40.
28. Lavelle, K.J., D.J. Doedens, S.A. Kleit, et al., Iodine absorption in burn patients treated topically with povidone-iodine. Clin Pharmacol Ther,1975.17(3):p.355-62.
29. Rath, T. andG. Meissl, Induction of hyperthyroidism in bum patients treated topically with povidone-iodine. Bums Incl Therm Inj,1988.14(4):p.320-2.
30. Nobukuni, K. andS. Kawahara, Thyroid function in nurses: the influence of povidone-iodine hand washing and gargling. Dermatology,2002.204 Suppl 1:p.99-102.
31. Ader, A.W., T.L. Paul, W. Reinhardt, et al., Effect of mouth rinsing with two polyvinylpyrrolidone-iodine mixtures on iodine absorption and thyroid function. J Clin Endocrinol Metab,1988.66(3):p.632-5.
32. Tomoda, C., H. Kitano, T. Uruno, et al., Transcutaneous iodine absorption in adult patients with thyroid cancer disinfected with povidone-iodine at operation. Thyroid,2005.15(6):p.600-3.
33. Purdon, C.H., C.G. Azzi, J. Zhang, et al., Penetration enhancement of transdermal delivery--current permutations and limitations. Crit Rev Ther Drug Carrier Syst,2004.21(2):p.97-132.
34. Benson, H.A., Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv, 2005.2(1):p.23-33.
35. Nanda, A., S. Nanda, and N.M. Ghilzai, Current developments using emerging transdermal technologies in physical enhancement methods. Curr Drug Deliv,2006.3(3):p.233-42.
36. Tanner, J., Surgical hand antisepsis: the evidence. J Perioper Pract,2008.18(8):p.330-4,339.
37. Hsieh, H.F., H.H. Chiu, and F.P. Lee, Surgical hand scrubs in relation to microbial counts: systematic literature review. J Adv Nurs,2006.55(1):p.68-78.
38. Tanwar, Y.S., C.S. Chauhan, and A. Sharma, Development and evaluation of carvedilol transdermal patches. Acta Pharm,2007.57(2):p.151-9.
1. Hirsch, A.T., Z.J. Haskal, N.R. Hertzer, et al., ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic):a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation,2006.113(11):e463-654.
2. Prostanoids for chronic critical leg ischemia. A rand omized, controlled, open-label trial with prostagland in E1. The ICAI Study Group. Ischemia Cronica degli Arti Inferiori. Ann Intern Med, 1999.130(5):412-21.
3. Albers, M., A.C. Fratezi and N. De Luccia, Assessment of quality of life of patients with severe ischemia as a result of infrainguinal arterial occlusive disease. J Vasc Surg,1992.16(1):54-9.
4. Davies, N., S. Dobner, D. Bezuidenhout, et al., The dosage dependence of VEGF stimulation on scaffold neovascularisation. Biomaterials,2008.29(26):3531-8.
5. Adams, R.H. and K. Alitalo, Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol,2007.8(6):464-78.
6. Carmeliet, P., Mechanisms of angiogenesis and arteriogenesis. Nat Med,2000.6(4):389-95.
7. Helisch, A. and W. Schaper, Arteriogenesis: the development and growth of collateral arteries. Microcirculation,2003.10(1):83-97.
8. Simons, M., Angiogenesis: where do we stand now? Circulation,2005.111(12):1556-66.
9. Murray, C.D., The Physiological Principle of Minimum Work: I. The Vascular System and the Cost of Blood Volume. Proc Natl Acad Sci U S A,1926.12(3):207-14.
10. Phelps, E.A. and A.J. Garcia, Update on therapeutic vascularization strategies. Regen Med,2009.4(1): 65-80.
11. Chen, R.R., E.A. Silva, W.W. Yuen, et al., Integrated approach to designing growth factor delivery systems. FASEB J,2007.21(14):3896-903.
12. Gerhardt, H., M. Golding, M. Fruttiger, et al., VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol,2003.161(6):1163-77.
13. Dellian, M., B.P. Witwer, H.A. Salehi, et al., Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am J Pathol,1996.149(1):59-71.
14. Hao, X., E.A. Silva, A. Mansson-Broberg, et al., Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc Res,2007. 75(1):178-85.
15. Chen, R.R., E.A. Silva, W.W. Yuen, et al., Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm Res,2007.24(2):258-64.
16. Richardson, T.P., M.C. Peters, AB. Ennett, et al., Polymeric system for dual growth factor delivery. Nat Biotechnol,2001.19(11):1029-34.
17. Marui, A, A Kanematsu, K. Yamahara, et al., Simultaneous application of basic fibroblast growth factor and hepatocyte growth factor to enhance the blood vessels formation. J Vasc Surg,2005.41(1): 82-90.
18. Shyu, K.G., H. Chang and J.M. Isner, Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. Life Sci,2003.73(5):563-79.
19. Rajagopalan, S., J. Olin, S. Deitcher, et al., Use of a constitutively active hypoxia-inducible factor- 1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation,2007.115(10):1234-43.
20. Carmeliet, P., VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med,2000. 6(10):1102-3.
21. Marui, A., Y. Tabata, S. Kojima, et al., A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel: an initial report of the phase I-IIa study. Gire J,2007.71(8):1181-6.
22. Bobek, V., O. Taltynov, D. Pinterova, et al., Gene therapy of the ischemic lower limb--Therapeutic angiogenesis. Vascul Pharmacol,2006.44(6):395-405.
23. Isner, J.M., A. Pieczek, R Schainfeld, et al., Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet,1996.348(9024):370-4.
24. Makinen, K., H. Manninen, M. Hedman, et al., Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a rand omized, placebo-controlled, double-blinded phase II study. Mol Ther,2002.6(1):127-33.
25. Kusumanto, Y.H., V. van Weel, N.H. Mulder, et al., Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind rand omized trial. Hum Gene Ther,2006.17(6):683-91.
26. Comerota, A.J., R.C. Throm, K.A. Miller, et al., Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg,2002.35(5):930-6.
27. Nikol, S., I. Baumgartner, E. Van Belle, et al., Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther,2008.16(5): 972-8.
28. Powell, RJ., M. Simons, F.O. Mendelsohn, et al., Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation,2008.118(1):58-65.
29. Chae, J.K., I. Kim, S.T. Lim, et al., Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler Thromb Vasc Biol,2000.20(12): 2573-8.
30. Suri, C., J. McClain, G. Thurston, et al., Increased vascularization in mice overexpressing angiopoietin-1. Science,1998.282(5388):468-71.
31. Asahara, T., T. Murohara, A. Sullivan, et al., Isolation of putative progenitor endothelial cells for angiogenesis. Science,1997.275(5302):964-7.
32. Friedrich, E.B., K. Walenta, J. Scharlau, et al., CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res,2006.98(3):e20-5.
33. Peichev, M., A.J. Naiyer, D. Pereira, et al., Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood,2000.95(3):952-8.
34. Pelosi, E., M. Valtieri, S. Coppola, et al., Identification of the hemangioblast in postnatal life. Blood, 2002.100(9):3203-8.
35. Shi, Q., S. Rafii, M.H. Wu, et al., Evidence for circulating bone marrow-derived endothelial cells. Blood,1998.92(2):362-7.
36. Wassmann, S., N. Wemer, T. Czech, et al., Improvement of endothelial function by systemic transfusion of vascular progenitor cells. Circ Res,2006.99(8):e74-83.
37. Griese, D.P., A. Ehsan, L.G. Melo, et al., Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts:implications for cell-based vascular therapy. Circulation,2003.108(21):2710-5.
38. Kong, D., L.G. Melo, M. Gnecchi, et al., Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation,2004.110(14):2039-46.
39. Crosby, J.R, W.E. Kaminski, G. Schatteman, et al., Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Girc Res,2000.87(9):728-30.
40. Kalka, C., H. Masuda, T. Takahashi, et al., Transplantation of ex vivo expand ed endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A,2000.97(7):3422-7.
41. Rehman, J., J. Li, C.M. Orschell, et al., Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation,2003.107(8): 1164-9.
42. Murayama, T., OM Tepper, M. Silver, et al., Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo. Exp Hematol,2002.30(8):967-72.
43. Tateishi-Yuyama, E., H. Matsubara, T. Murohara, et al., Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a rand omised controlled trial. Lancet,2002.360(9331):427-35.
44. Ziegelhoeffer, T., B. Fernand ez, S. Kostin, et al., Bone marrow-derived cells do not incorporate into the adult growing vasculature. Clrc Res,2004.94(2):230-8.
45. Assmus, B., V. Schachinger, G Teupe, et al., Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation,2002.106(24):3009-17.
46. Huang, P.P., X.F. Yang, S.Z. Li, et al., Rand omised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost,2007.98(6):1335-42.
47. Jiang, Y., B.N. Jahagirdar, RL. Reinhardt, et al., Pluripotency of mesenchymal stem cells derived from adult marrow. Nature,2002.418(6893):41-9.
48. Chamberlain, G., J. Fox, B. Ashton, et al., Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells,2007.25(11): 2739-49.
49. Psaltis, P.J., A.G Zannettino, S.G. Worthley, et al., Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells,2008.26(9):2201-10.
50. Kawamoto, A., T. Tkebuchava, J. Yamaguchi, et al., Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation, 2003.107(3):461-8.
51. Kinnaird, T., E. Stabile, M.S. Burnett, et al., Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation,2004.109(12):1543-9.
52. Suuronen, E.J., J. Price, J.P. Veinot, et al., Comparative effects of mesenchymal progenitor cells, endothelial progenitor cells, or their combination on myocardial infarct regeneration and cardiac function. J Thorac Cardiovasc Surg,2007.134(5):1249-58.
1 Park KH, Lim C, et al, Prevalence of aortic intimal defect in surgically treated acute type A intramural hematoma, Ann Thorac Surg.2008 Nov;86(5):1501.
2 Coady MA, Rizzo JA, Elefteriades JA. Pathologic variants of thoracic aortic dissections. Penetrating atherosclerotic ulcers and intramural hematomas. Cardiol Clin 1999;17:637-57.
3 Nienaber CA, Sievers HH. Intramural hematoma in acute aortic syndrome: more than one variant of dissection? Circulation.2002,406:284-285.
4 Ganaha F; Miller DC, et al, Prognosis of aortic intramural hematoma with and without penetrating atherosclerotic ulcer: a clinical and radiological analysis. Circulation 2002 Jul 16;106(3):342-8.
5 Cho KR, Stanson AW, Potter DD, et al. Penetrating atherosclerotic ulcer of the descending thoracic aorta and arch. J Thorac Cardiovasc Surg 2004;127:1393-401.
6 Sundt TM.Intramural hematoma and penetrating atherosclerotic ulcer of the aorta-Ann Thorac Surg.2007 Feb;83(2):S835-41; discussion S846-50.
7 Meszaros I; Morocz J, et al, Epidemiology and clinicopathology of aortic dissection, Chest 2000 May,117(5):1271-8.
8 Clouse WD; Hallett JW Jr, et al, Acute aortic dissection: population-based incidence compared with degenerative aortic aneurysm rupture, Mayo Glin Proc 2004 Feb;79(2):176-80.
9 Hagan PG; Nienaber CA; et al, The International Registry of Acute Aortic Dissection (IRAD):new insights into an old disease, JAMA 2000 Feb 16;283(7):897-903.
10 Nienaber CA; Fattori R, et al, Gender-related differences in acute aortic dissection, Circulation 2004 Jun 22;109(24):3014-21. Epub 2004 Jun 14.
11 Evangelista A; Mukherjee D, et al, Acute intramural hematoma of the aorta: a mystery in evolution. Circulation 2005 Mar 1;111(8):1063-70. Epub 2005 Feb 14.
12 Nienaber CA; Eagle KA, Aortic dissection: new frontiers in diagnosis and management: Part Ⅰ:from etiology to diagnostic strategies. Circulation 2003 Aug 5;108(5):628-35.
13 Nallamothu BK, Mehta RH, et al, Syncope in acute aortic dissection: diagnostic, prognostic, and clinical implications. Am J Med.2002;113:468-471.
14 Park SW; Hutchison S, et al, Association of painless acute aortic dissection with increased mortality. Mayo Clin Proc 2004 Oct;79(10):1252-7.
15 Kamp TJ, Goldschmidt-Clermont PJ, et al, Myocardial infarction, aortic dissection, and thrombolytic therapy. Am Heart J.1994;128:1234-1237.
16 Hansen MS, Nogareda GJ, Hutchison SJ. Frequency of and inappropriate treatment of misdiagnosis of acute aortic dissection. Am J Cardiol.2007 Mar 15;99(6):852-6.
17 von Kodolitsch Y; Schwartz AG; Nienaber CA, Clinical prediction of acute aortic dissection, Arch Intern Med 2000 Oct 23;160(19):2977-82.
18 Vilacosta I; San Roman JA, et al, Natural history and serial morphology of aortic intramural hematoma: a novel variant of aortic dissection. Am Heart J 1997 Sep;134(3):495-507.
19 Ohlmann P, Faure A, et al, Lower circulating Sta-Liatest D-Di levels in patients with aortic intramural hematoma compared with classical aortic dissection. Crit Care Med.2009 Mar;37(3):899-901.
20 Isselbacher EM; Gigarroa JE; Eagle KA, Cardiac tamponade complicating proximal aortic dissection. Is pericardiocentesis harmful? Circulation 1994 Nov;90(5):2375-8.
21 Tsai TT; Evangelista A, et al, Partial thrombosis of the false lumen in patients with acute type B aortic dissection. N Engl J Med.2007 Jul 26;357(4):349-59.
22 Mehta RH; O'Gara PT, et al, Acute type A aortic dissection in the elderly: clinical characteristics, management, and outcomes in the current era. J Am Coll Cardiol 2002 Aug 21;40(4):685-92.
23 Jakob H, Tsagakis K, et al, Combining classic surgery with descending stent grafting for acute DeBakey type I dissection. Ann Thorac Surg.2008 Jul;86(1):101-2.
24 Penn MS; Smedira N, et al, Does coronary angiography before emergency aortic surgery affect in-hospital mortality? J Am Coll Cardiol 2000 Mar 15;35(4):889-94.
25 DeSanctis RW;Doroghazi RM, et al. Aortic dissection. N Engl J Med 1987 Oct22;317(17):1060-7.
26 Umana JP; Lai DT, et al, Is medical therapy still the optimal treatment strategy for patients with acute type B aortic dissections? J Thorac Cardiovasc Surg 2002 Nov;124(5):896-910.
27 Shimokawa T, Horiuchi K, et al, Outcome of surgical treatment in patients with acute type B aortic dissection, Ann Thorac Surg.2008 Jul;86(1):107-8.
28 Kusagawa H; Shimono T, et al, Changes in false lumen after transluminal stent-graft placement in aortic dissections: six years experience, Circulation 2005 Jun 7;111(22):2951-7. Epub 2005 May31.
29 王深明,Stanford A型主动脉夹层的血管腔内治疗,外科理论与实践,2007,12(1)：7-9.
30 常光其,李晓曦,等,腔内修复联合旁路手术治疗DeBakey I型升主动脉夹层,中华实用外科杂志,2005,25(12)
31 Eggebrecht H; Nienaber CA, et al, Endovascular stent-graft placement in aortic dissection: a meta-analysis, Eur Heart J.2006 Feb;27(4):489-498. Epub 2005 Oct 14.
32 Parker JD, Golledge J. Outcome of endovascular treatment of acute type B aortic dissection. Ann Thorac Surg.2008 Nov;86(5):1707-12.
33 Nienaber CA; Fattori R, et al, Nonsurgical reconstruction of thoracic aortic dissection by stent-graft placement. N Engl J Med 1999 May20;340(20):1539-45.
34 Endovascular therapy for Stanford type B aortic dissection in 102 cases. Asian Journal of Surgery. 2005,28(4):271-276.
35 石赞,符伟国等,150例Stanford B型主动脉夹层动脉瘤的手术回顾。外科理论与实践,2005,10(1)：45-49.
36 Strategies for managing the insufficiency of the proximal landing zone during endovascular thoracic aortic repair. Chinese Medical Journal,2005,118(13):1066-1071.
37 邵明哲,符伟国等,累及肠系膜上动脉的Stanford B型夹层主动脉瘤的治疗.中华普通外科杂志,200722(1)：58-60.
38 Retrograde Type A Aortic Dissection Following Endovascular Stent-graft Placement for Treatment of Type B Dissection. Circulation,2009,February 10,735-744.
39 Slonim SM; Miller DC, et al, Percutaneous balloon fenestration and stenting for life-threatening ischemic complications in patients with acute aortic dissection. J Thorac Cardiovasc Surg 1999 Jun;117(6):1118-26.
40 Erbel R; Alfonso F, et al, Diagnosis and management of aortic dissection. Eur Heart J 2001 Sep;22(18):1642-81.
41 Maraj R; Rerkpattanapipat P, et al, Meta-analysis of 143 reported cases of aortic intramural hematoma. Am J Cardiol 2000 Sep 15;86(6):664-8.
42 von Kodolitsch Y; Csosz SK, et al, Intramural hematoma of the aorta: predictors of progression to dissection and rupture. Circulation 2003 Mar 4;107(8):1158-63.
43 Shimokawa T, Ozawa N, et al, Intermediate-term results of surgical treatment of acute intramural hematoma involving the ascending aorta. Ann Thorac Surg.2008 Mar,85(3):982-6
44 Moizumi Y; Komatsu T, et al, Clinical features and long-term outcome of type A and type B intramural hematoma of the aorta, J Thorac Cardiovasc Surg 2004 Feb;127(2):421-7.
45 Kaji S; Akasaka T, et al, Long-term prognosis of patients with type B aortic intramural hematoma. Circulation 2003 Sep 9;108 Suppl 1:Ⅱ307-11.
46 Tittle SL, Lynch RJ, Cole PE, et al. Midterm follow-up of penetrating ulcer and intramural hematoma of the aorta. J Thorac Cardiovasc Surg 2002;123:1051-9.
47 Stanson AW, Kazmier FJ, et al. Penetrating atherosclerotic ulcers of the thoracic aorta: natural history and clinicopathologic correlations. Ann Vasc Surg 1986;1:15-23.
48 Coady MA, Rizzo JA, et al. Penetrating ulcer of the thoracic aorta: what is it? How do we recognize it? How do we manage it? J Vasc Surg 1998;27:1006-1015
49 Grabenwoger M, Fleck T, Czerny M, et al. Endovascular stent graft placement in patients with acute thoracic aortic syndromes. Eur J Cardiothorac Surg 2003;23:788-93.
50 Demers P; Miller DC, et al, Stent-graft repair of penetrating atherosclerotic ulcers in the descending thoracic aorta: mid-term results. Ann Thorac Surg 2004 Jan;77(1):81-6.
51 Botta L, Buttazzi K, et al, Endovascular repair for penetrating aatherosclerotic ulcers of the descending thoracic aorta: early and mid-term result. Ann Thorac Surg 2008 Mar;85(3):987-92
52 Brinster DR, Wheatley GH 3rd, et al. Are penetrating aortic ulcers best treated using an endovascular approach, Ann Thorac Surg.2006 Nov;82(5):1688-91.
53 Dalainas I, Nano G, et al. Endovascular treatment of penetrating aortic ulcers: mid-term results. Eur J Vasc Endovasc Surg.2007 Jul;34(1):74-8.
54 Girn HR, McPherson S, et al. Short series of emergency stent-graft repair of symptomatic penetrating thoracic aortic ulcers (PTAU). Vasc Med.2009 May;14(2):123-8.